Anushua Sinha, MD, MPH

Director
Merck and Co Inc.
Rahway, NJ, United States

Anushua is a Clinical Director at Merck & Co., where she is the Product Development Team Lead for clesrovimab, an investigational anti-RSV preventative monoclonal antibody. Anushua came to Merck in 2016 from Rutgers University, where she was on the faculty of both the Rutgers School of Public Health and Rutgers New Jersey Medical School. She also served as infectious disease attending physician at The University Hospital, Newark NJ, and continued to see outpatients there on a pro bono basis until 2021. She completed her clinical training at Harvard Medical School, Massachusetts General Hospital, and the Brigham and Women’s Hospital. She completed her research training at the Channing Laboratory and the Harvard School of Public Health.

Disclosure(s): Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 166 - A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants

  Thursday, October 17, 2024
  2:09 PM – 2:21 PM US PT

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT